Therapeutic advances and application of PARP inhibitors in breast cancer
Translational Oncology · 2025-07 · 57 · 102410
DOI: 10.1016/j.tranon.2025.102410 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2025-07. Verfasst von Teng Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China; Department of Oncology, Shanghai Medical College…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China, Shanghai Medical College of Fudan University.
Abstract (Originalsprache)
Targeting of DNA repair pathway is the main therapeutic approach for BRCA1 and BRCA2 associated tumors, including breast cancer. BRCA1/2 genes play a pivotal role in HRR pathway. Mutations in BRCA1/2 leads to DDR deficiency, which cause the increasing of genome instability, thus rendering cancer cells vulnerable to inhibition of DNA repair related proteins, such as PARP1. Pre-clinical studies has demonstrated that cancer cells with BRCA1/2 deficient are sensitive to PARPi, which are an emerging class of small molecule drug. Several clinical trials demonstrated the promising efficacy of PARP inhibitors for BRCA1/2 mutated breast cancer patient through selectively induce synthetic lethality cancer cells. Currently, four PARP inhibitors had been approved by FDA for clinical use. PARPi demonstrated to improve progression-free survival, while resistance to PARPi is inevitable. In this review article, we highlighted the advances in the PARPi clinical trials, resistance mechanism and coping strategies in breast cancer patients. We also summarized the international guideline and recommendations on PARP inhibitor usage in breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China.
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China. Electronic address: ji…
Förderung
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Shanghai Medical College of Fudan University
Zitieren
APA
Zhou, T., & Zhang, J. (2025). Therapeutic advances and application of PARP inhibitors in breast cancer. Translational Oncology, 57, 102410. https://doi.org/10.1016/j.tranon.2025.102410
Vancouver
Zhou T, Zhang J. Therapeutic advances and application of PARP inhibitors in breast cancer. Translational Oncology. 2025;57:102410. doi:10.1016/j.tranon.2025.102410
BibTeX
@article{Zhou2025,
author = {Zhou, Teng and Zhang, Jian},
title = {Therapeutic advances and application of PARP inhibitors in breast cancer},
journal = {Translational Oncology},
year = {2025},
volume = {57},
pages = {102410},
doi = {10.1016/j.tranon.2025.102410}
}
EUVIMED